已收盘 07-02 16:00:00 美东时间
-2.760
-3.33%
今日重点评级关注:Chardan Capital:维持EyePoint"买入"评级,目标价从29美元升至65美元;康托·菲茨杰拉德:维持Hyperliquid Strategies"超配"评级,目标价从8美元升至18.4美元
07-02 18:41
今日重点评级关注:Citizens:维持DBV Technologies"跑赢大市"评级,目标价从47美元升至55美元;康托·菲茨杰拉德:维持BioCryst制药"超配"评级,目标价从27美元升至29美元
07-01 10:40
RBC Capital analyst Arun Viswanathan maintains Solstice Advanced Mat (NASDAQ:SOLS) with a Outperform and raises the price target from $100 to $102.
06-30 22:21
今日重点评级关注:Ascendiant Capital:维持IGC Pharma"买入"评级,目标价从5.25美元升至5.5美元;Ascendiant Capital:维持Lucid Diagnostics"买入"评级,目标价从9美元升至9.25美元
06-09 11:33
今日重点评级关注:瑞银:维持DraftKings"买入"评级,目标价从43美元升至49美元;Needham:维持Planet Labs"买入"评级,目标价从40美元升至53美元
06-08 11:33
BMO Capital analyst John McNulty maintains Solstice Advanced Mat (NASDAQ:SOLS) with a Outperform and raises the price target from $92 to $101.
06-05 21:02
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从15美元升至35美元;韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从36美元升至37美元
05-11 15:43
UBS analyst Joshua Spector maintains Solstice Advanced Mat (NASDAQ:SOLS) with a Neutral and raises the price target from $87 to $88.
05-09 05:39
华盛资讯5月7日讯,Solstice Advanced Materials, Inc.公布2026财年Q1业绩,公司Q1营收9.91亿美元,同比增长10.5%,归母净利润0.85亿美元,同比下滑36.6%。
05-07 10:39
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03